Publications by authors named "Yann Dean"

Claim this Profile
S
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.
Mélodie Grandin, Markus Meier, Jean Guy Delcros, Denise Nikodemus, Raphael Reuten, Yann Dean

Cancer Cell· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
Cathelijne Kloks, Claudia Berger, Pierre Cortez, Yann Dean, Julia Heinrich

J Immunol Methods· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a surrogate murine antibody to model anti-human CD3 therapies.
Fabien Dépis, Eric Hatterer, Romain Ballet, Bruno Daubeuf, Laura Cons, Yann Dean

MAbs· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical models used for immunogenicity prediction of therapeutic proteins.
Vera Brinks, Daniel Weinbuch, Matthew Baker, Yann Dean, Philippe Stas

Pharm Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.
Yann Dean, Fabien Dépis, Marie Kosco-Vilbois

Swiss Med Wkly· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments.
Fabien Dépis, Eric Hatterer, Céline Lamacchia, Jean-Marc Waldburger, Cem Gabay, Yann Dean

Arthritis Rheum· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
C Janneke van der Woude, Pieter Stokkers, Ad A van Bodegraven, Gert Van Assche, Zbigniew Hebzda, Yann Dean

Inflamm Bowel Dis· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.
Irene Dunn-Siegrist, Olivier Leger, Bruno Daubeuf, Yves Poitevin, Fabien Dépis, Yann Dean

J Biol Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice.
Sabine Steffens, Fabienne Burger, Graziano Pelli, Yann Dean, Greg Elson

Circulation· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.
Philippe Gasque, Jim W Neal, Sim K Singhrao, Eamon P McGreal, Yann D Dean

Mol Neurobiol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis